A phase IV, multi-center, randomized, open-label study of PCECV (Rabipur) comparing the immunogenicity and safety of two different simulated post exposure schedules (Zagreb 2-1-1 versus Essen regimen 1-1-1-1-1) in Healthy Indian subjects - Rabipur study.

Trial Profile

A phase IV, multi-center, randomized, open-label study of PCECV (Rabipur) comparing the immunogenicity and safety of two different simulated post exposure schedules (Zagreb 2-1-1 versus Essen regimen 1-1-1-1-1) in Healthy Indian subjects - Rabipur study.

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Rabies vaccine (Primary)
  • Indications Rabies
  • Focus Pharmacodynamics
  • Sponsors Novartis
  • Most Recent Events

    • 02 Dec 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Aug 2011 New source identified and integrated (Clinical Trials Registry - India).
    • 22 Jul 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top